BioVascular: Platelet mediation

Preventing vascular graft failure by pharmaceutical means is not an area that has seen much success, but BioVascular Inc. hopes its saratin can prevent the buildup of platelets inside blood vessels that often causes graft failure. The company expects interim data from a pair of European Phase I/II trials next year.

Saratin is a recombinant version of a 12-kD polypeptide derived from leech saliva that helps keep the blood vessel open after

Read the full 711 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE